Redeye Feed

2026-02-19 09:43:00 Scandinavian ChemoTech (Q4 Review): Seasonal softness, intact growth case

2026-02-19 09:41:00 EG7 (Q4 Review): Balance sheet clean-up supports valuation improvement

2026-02-19 09:40:00 Momentum Group (Q4 review): Temporary hiccup

2026-02-19 09:39:00 SSH (Q4 Review): 2026 – The Year for Growth

2026-02-19 09:38:00 Modelon (Q4 Review): Operational leverage in place for the 2026 growth pivot

2026-02-19 09:36:00 Isofol Medical (Q4 Review): Translational year ahead

2026-02-19 09:35:00 Senzime (Q4 Review): Solid report and a positive 2026 outlook

2026-02-19 09:34:00 Avensia (Q4 review): Challenging market dynamics continue – opportunities in B2B, back-end, and AI

2026-02-18 12:31:00 Cinclus Pharma (Q4 Review): Phase III advancing on time

2026-02-18 11:30:00 Senzime (Q4 Initial take): Sales spot on to our estimate

2026-02-18 11:28:00 Boreo (Q4 review): Solid execution, optimistic outlook

2026-02-18 11:27:00 Relais (Q4 review): Stable performance despite challenges

2026-02-18 11:26:00 Truecaller (Q4 Review): Transformative pivot amid advertising headwinds

2026-02-18 11:25:00 Camurus (Q4 review): Temporary UK Setback

2026-02-18 11:24:00 Smart Eye (Q4 Review): Accelerating while the market hits the brake

2026-02-18 11:22:00 Catella (Q4 Review): Clean core beat fails to prevent 14% share decline as SEK151m impairment offsets strength

2026-02-18 11:21:00 Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence

2026-02-17 09:54:00 Correction: Relais Group (Q4 interview): Redeye speaks with CEO Christian Gebauer

2026-02-17 09:07:00 SSH (Q4 Initial take): A softer quarter, as expected

2026-02-17 08:57:00 Relais Group (Q4 interview): Redeye speaks with CEO Christian Gebauer

2026-02-17 08:26:00 Xspray Pharma (Q4 Review): A pivotal year ahead

2026-02-17 08:25:00 Genovis (Q4 review): Growth and a big cash pile at rapidly contracting multiples

2026-02-17 08:23:00 Invisio (Q4 Review): Strong year-end and positive outlook

2026-02-17 08:21:00 Polygiene Group (Q4 Review): Soft Finish to 2025, Long-Term Opportunity Intact

2026-02-17 08:19:00 Nitro Games (Q4 Review): Solid year-end performance

2026-02-16 16:42:00 Mendus (Q4 review): CML a New Value Driver

2026-02-16 11:20:00 Nitro Games (Q4 Initial take): Solid beat driven by strong profitability

2026-02-16 10:56:00 Devyser (Q4 Interview): Redeye has interviewed CEO Jan Wahlström

2026-02-16 10:54:00 Alligator Bioscience (Q4 Review): Deal or No Deal

2026-02-16 10:52:00 RaySearch Laboratories (Q4 Review): A beaming end it was

2026-02-16 10:51:00 Embracer (Q3 Review): Stable near-term outlook, game pipeline supports upside in 2026/27E

2026-02-16 10:50:00 Nekkar (Q4 Review): New Deals and Tender Pipeline Support Rebound

2026-02-16 10:48:00 BeammWave (Q4 Review): Execution over exploration

2026-02-16 10:44:00 Ferroamp (Q4 Review): Positioned for financial inflection in 2026

2026-02-16 10:43:00 Carasent (Q4 review): New products and sales initiatives to drive growth in 2026

2026-02-13 13:18:00 Relais (Q4 initial take): Solid profitability, softer organic growth

2026-02-13 13:08:00 Active Biotech (Q4 Review): Tasqinimod Recruiting Again

2026-02-13 13:07:00 Sprint Bioscience (Q4 Review): Promising development

2026-02-13 13:05:00 Acarix (Q4 review): A solid end to 2025

2026-02-13 13:04:00 Stille: (Q4 review): Easing headwinds and solid outlook at 11x current year EV/EBITDA

2026-02-13 13:03:00 Devyser Diagnostics (Q4 Review): Jaw-dropping EBIT margin

2026-02-13 13:02:00 Lytix Biopharma (Q4 Review): Well-Funded to Deliver in 26′

2026-02-13 12:59:00 W5 Solutions (Q4 Review): Strong year-end and positive outlook

2026-02-13 12:59:00 Neola Medical (Q4 Review): Eyes on upcoming clinical data

2026-02-13 12:58:00 Tradedoubler (Q4 Review): Double Digit Metapic, Single Digit Multiple

2026-02-13 12:57:00 Vertiseit (Q4 review): Long-term story intact – AI resilience from the back-end

2026-02-13 12:56:00 Lime (Q4 review): Solid fundamentals despite AI squeeze

2026-02-13 12:55:00 CombinedX (Q4 review): Entering 2026 with renewed vision

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Vem äger bolaget?

Redeye

Prenumeration

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden